Introduction
Interleukin-6 (IL-6), a pleiotropic cytokine, plays an important role in gene activation, proliferation, and differentiation in a wide spectrum of cell types. [1] [2] [3] In B cell development, IL-6 has been shown to induce terminal maturation of B lymphocytes into antibody producing plasma cells. 4, 5 Increased immunoglobulin synthesis and secretion, down-regulation of surface major histocompatibility (MHC) class II expression, a marked increase in secretory apparatus, and cell cycle arrest upon IL-6 stimulation are the hallmarks of normal B cell terminal differentiation. 5 Antibody-secreting plasma cells are usually short-lived and do not proliferate, having a life span of 3 to 6 weeks, 6 and ultimately undergo apoptosis. In contrast, IL-6 has been shown to act as the primary growth factor for freshly isolated myeloma plasma cells as well as myeloma cell lines. 7 In some cases, it even functions as an anti-apoptotic agent against therapeutic treatments in myeloma. [8] [9] [10] [11] IL-6 is produced by a variety of cell types including bone marrow stromal cells. 2, 9 The IL-6 receptor complex is composed of an ␣ chain (IL-6-specific binding unit gp80) and a ␤ chain (commonly shared signal transducing unit gp130). Two major signaling pathways through the gp130 transducing subunit are Janus kinases -signal transducers and activators of transcription (Jak-STAT) and Ras and mitogen-activated protein kinases (Ras-MAPK). 2, 12 Upon IL-6 stimulation, the gp80 binds to IL-6 and clusters with the signaling subunit gp130. Subsequently, the tyrosine residues on the gp130 are phosphorylated by tyrosine kinases JAKs that are constitutively bound to the gp130. Phosphorylated tyrosine residues on the gp130 then serve as docking sites for other SH2 containing molecules such as STAT1, STAT3, SOCS 3, or SHP-2. 12 Upon docking, STAT1 and 3 also become phosphorylated by the activated tyrosine kinases, form either homodimers or heterodimers, and translocate to the nucleus, where they regulate transcription of target genes.
STAT proteins are sometimes referred to as 'fast-track' signaling molecules because they can directly transduce a signal from the plasma membrane to the gene. STAT3 has been recognized as an essential molecule for gp130-mediated cell growth, survival, and differentiation. 1, 13 Recently, constitutive activation of STAT3 in myeloma has been suggested to confer resistance to apoptosis by up-regulating anti-apoptotic molecules such as bcl-2 and bcl-X L .
14 Furthermore, the constitutive activation of STAT3 was reported recently to associate with acquisition of an interleukin 6-independent phenotype in murine plasmacytomas and hybridomas. 15 Interestingly, signaling kinetics and duration in PC12 cells has been described to alter or give rise to distinct cell fate such as proliferation or differentiation. 16 Because of the potential relationship of signaling kinetics and cell fate, in this study we compared the kinetics and influences of IL-6 signaling in myeloma cell lines that proliferate in response to IL-6 and in a lymphoblast cell line that terminally differentiates, cell cycle arrests, and undergoes apoptosis in response to IL-6.
Materials and methods

Cell culture, reagents and antibodies
Myeloma cell lines ANBL6 plxsn (ANBL6), KAS 6/1, and human B lymphoblastiod cell line CESS (IgG-bearing) were maintained in RPMI 1640 supplemented with 10% FCS, l-glutamine, penicillin-streptomycin at 37°C and 5% CO 2 . IL-6-dependent lines (ANBL6 and KAS 6/1) were also supplemented with 0.5 ng/ml IL-6 (R&D Systems, Minneapolis, MN, USA) every 4 days. Ten ng/ml of IL-6 was used in all the experiments and added in every 12 h unless noted. Cells numbers were maintained at approximately 5 × 10 5 cells/ml. Before all experiments, IL-6-dependent myeloma cells were starved of IL-6 for 3 days. IL-6 and IL-6sR were obtained from R&D Systems. Propidium iodide was obtained from Sigma (St Louis, MO, USA). Anti-p-STAT3, SHP-2, and Actin antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-phosphotyrosine 4G10 and anti-gp130 antibodies were purchased from Upstate Biotechnology (Lake Placid, NY, USA). Anti-bcl-X L antibodies were obtained from Transduction Laboratories (San Jose, CA, USA).
Anti-human IgG and lamda light chain antibodies were purchased from Biosource International (Camarillo, CA, USA).
Analysis of apoptosis and cell cycle
2 × 10 5 cells were collected and pelleted at the times indicated. They were then resuspended in 500 l of hypotonic solution (50 g/ml PI in 0.1% sodium citrate plus 0.1% Triton X-100) and incubated for at least 4 h at 4°C in the dark. Analysis of the nuclei (both apoptotic and intact) was performed using FACSCalibur (Becton Dickinson, Mountain View, CA, USA). Apoptotic nuclei were detected as a heterogeneous subdiploid population to the left of intact nuclei in G 0 -G 1 in the histograms. Any changes in cell cycle distribution were also detected by the same method.
Immunoprecipitation and Western blot analysis
2 × 10 6 cells were chilled on ice and collected from IL-6 stimulated samples at the time indicated and washed once in ice-cold 1× PBS. Fresh myeloma cells were collected from patients' bone marrow (with consent and IRB approval) and CD138-positive cells were sorted. Sorted cells were immediately frozen. Cells were then lysed in ice-cold RIPA buffer (40 mm Tris-HCl pH 7.9, 0.1% NP-40, 0.25% sodium deoxycholate, 1 mm EDTA, 1 mm PMSF, 1 g/ml aprotinin, 1 g/ml leupeptin, 1 g/ml pepstatin, 1 mm Na 3 VO 4 , 1 mm NaF). Cell lysates were immunoprecipitated with the indicated antibodies and mixed with protein A/G agarose beads at 4°C overnight. Immunoprecipitations were washed five times with ice-cold RIPA lysis buffer and resolved on SDS-polyacrylamide gels, electrotransferred to PVDF membrane. The membrane was blocked in 5% dry milk in PBS for 1 h and incubated with the primary antibodies at the appropriate dilution overnight at 4°C, followed by incubation of appropriate secondary antibodies for 1 h. The membranes were washed three times for 5 min each in PBS with 0.1% Tween 20 between each step, developed by using enhanced chemiluminescence detection kit (Amersham, Piscataway, NJ, USA), and exposed to X-ray films.
Electrophoretic mobility shift assay
To obtain nuclear extracts, stimulated cells were lysed on ice for 10 min in hypotonic buffer, which contained 20 mm HEPES, pH 7.9, 0.2% NP-40, 10% glycerol, 10 mm KCl, 1 mm EDTA, 1 mm Na 3 VO 4 , 1 mm PMSF, 10 g/ml aprotinin, 10 g/ml leupeptin, 20 mm NaF, and 1 mm DTT. Lysates were centrifuged at 13 000 r.p.m. at 4°C for 1 min. Supernatants were collected as the cytoplasmic fraction. Pellets were used to prepare nuclear extracts by resuspending in 25 l of high salt buffer (hypotonic buffer supplemented with 20% glycerol and 420 mm NaCl). Resuspended lysates were incubated at 4°C for 30 min with gentle rocking. After centrifugation at 13 000 r.p.m. for 15 min at 4°C, the supernantants were collected as the nuclear extracts. STAT3 DNA binding activity was assayed using the sis-inducible elements (SIE) of c-fos DNA sequence (upper strand 5′-AGCTTCATTTCCC GTAATCCCTAAAGCT-3′). Ten g of the nuclear extracts were added to the binding buffer containing 10 mm HEPES, pH 7.9, 80 mm NaCl, 10% glycerol, 1 mm DTT, 1 mm EDTA, and 1.5 g of poly (dI-dC) with 32 P-labeled probe Leukemia (10 000 c.p.m.) for 30 min at room temperature. The protein-DNA complexes were resolved on a 4.5% polyacrylamide gel containing 2.5% glycerol in 0.25× TBE at room temperature. The gel was dried and exposed to phospho-imaging screen. The image was visualized by phosphorimager. Competitors (100×) were incubated for 30 min before addition of the labeled probe; NF-kB probe (upper strand 5′-TCTCAACA GAGGGGACTTTCCGAGAGGCCATCTGG-3′).
gp130 cell surface detection and IL-6sR-induced IL-6 signal transduction
IL-6 stimulated cells were collected at the time indicated and washed with ice-cold 1× PBS. 1 × 10 6 cells were stained with PE-conjugated anti-gp130 antibodies (Pharmingen, San Diego, CA, USA) on ice for 30 min. Cells were then washed twice with ice-cold 1× PBS, then resuspended in 500 l of 1× PBS. Cells were analyzed on FACSCalibur. PE-conjugated mouse isotype control was used. During IL-6 stimulation of CESS cells, 15 ng/ml of soluble IL-6 receptor (R&D Systems) was added at various time points. Whole cell lysates were collected as described above. STAT3 phosphorylation was detected by Western blotting. Actin antibodies were used as control.
Results
IL-6 promotes proliferation and cell survival in myeloma ANBL6 cells but induces cell cycle arrest and apoptosis in lymphoblast CESS cells
IL-6 is capable of inducing terminal differentiation in normal B cells. [3] [4] [5] However, IL-6 does not induce cell cycle arrest in malignant plasma cells; rather it promotes cell growth in myeloma. In order to study the differences in IL-6 signaling, we examined model cell lines which respond to IL-6 either by terminal differentiation (lymphoblast) or by proliferation (myeloma). After continuous addition of exogenous IL-6 (or co-cultured with bone marrow stromal cells -data not shown), cell cycle profiles of the ANBL6 and CESS cells at day 0 and day 5 were examined ( Figure 1 ). Propidium iodide stained cells were examined by flow cytometry. Myeloma ANBL6 showed a proliferative response to continuous IL-6 addition. The S/G2/M phase of the ANBL6 cell cycle increased from 6% to 24%. Our cell cultures typically show a background level of apoptosis ranging from 5 to 10%; thus, the apparent increase in apoptotic fraction with IL-6 addition was not significant. Similar results were obtained in the IL-6-dependent myeloma lines Kas6/1 and U266/p53 cells (data not shown). In contrast, the lymphoblast CESS cell line showed cell cycle arrest and underwent apoptosis, a characteristic of terminal differentiated B cells. In CESS cells, the S/G2/M phase of the cell cycle dropped from 26% to 13% in response to IL-6 and there was a significant apoptotic population observed in the subdiploid peak (38%) (Figure 1 ). These data demonstrate the two distinct responses of the model cell lines to IL-6, and were used to examine differences in IL-6 signaling.
Continuous addition of IL-6 caused a prolonged activation of STAT3 in ANBL6 but not in CESS
IL-6 is a multifunctional cytokine that is involved in cell proliferation, survival, and differentiation in many different cell Cell cycle analysis of CESS lymphoblastoid cells and ANBL6 myeloma in response to IL-6. Ten ng/ml of IL-6 was added to ANBL6 and CESS cells every 12 h for 6 days. Cells were maintained at 5 × 10 5 cells/ml and fed every 24 h in RPMI 1640 supplemented with 10% FCS. Cell cycle profiles were obtained by PI staining and examined by flow cytometry. Percent of apoptotic nuclei were shown on the left and percent of G2/M phases of cell cycle were shown on the right.
types.
1,2 IL-6 activates JAK/STAT and Ras pathways, and the JAK/STAT pathway has been suggested to be involved in proliferation, survival, and differentiation in some cell types. 17 Signaling kinetics have been implicated to determine cell fate. 16 Therefore, we examined the activation of STAT3 over time. IL-6 was added continuously in the cultures over a 6-day period or responding cells were co-cultured with bone marrow stromal cells that we previously have shown to produce continuous IL-6.
9,11 Whole cell lysates were collected at the times indicated and Western blotting was performed to examine STAT signaling (Figure 2a ). Prolonged STAT3 phosphorylation, indicating its activation, was observed in myeloma ANBL6 cells as late as day 6 (Figure 2a) . Myeloma cell lines, U266 and U266-p53, also showed prolonged STAT3 activation upon IL-6 stimulation (Figure 2b ). In contrast, only transient activation of STAT3 was observed in the lymphoblast CESS cells (Figure 2a ). Since lymphoblast CESS is IgG bearing, anti-human IgG antibodies were also used as an indicator of the CESS cells IL-6-induced differentiation (Figure 2a) .
In addition to comparing the phosphorylated STAT3 in ANBL6 and CESS cells, we also compared the DNA binding capability of the activated STAT3. Nuclear extracts were collected at the times indicated after IL-6 stimulation. A DNA binding pattern of P-STAT3 with kinetics similar to the Western blot analysis was observed in the mobility shift assay using the SIE probe and demonstrated the prolonged vs transient activation of STAT3 in ANBL6 and CESS cells respectively (Figure 3 ). Additional evidence of STAT3 activation was observed using anti-STAT3 specific phospho-serine 727 antibodies on the Western blotting analysis. When activated, both cell lines showed serine 727 phosphorylation of the STAT3 protein (data not shown).
The signal duration differences of STAT3 were not due to the different rate of receptor turnover nor to the absence of IL-6R
One explanation for the distinct STAT3 activation pattern in ANBL6 and CESS cells could be due to the differences in IL-
Figure 2
Comparison of STAT3 phosphorylation kinetics in response to IL-6. (a) Ten ng/ml of IL-6 was added to cultures every 12 h. ANBL6 and CESS whole cell lysates (wcl) were collected at the times indicated. One hundred g of wcl was loaded in each lane. The indicated primary antibodies were used for Western blotting. Anti-human IgG was used as one of the indicators of differentiation in CESS cells. Actin was used as loading control. Densitometry was performed and normalized with the actin control. (b) U266 and U266-p53 cell lines were starved of IL-6 for 3 days. Cells were then stimulated with 10 ng/ml of IL-6 for 8 h. Cells were collected at time points indicated and Western blotting was performed using phosphotyrosinespecific STAT3 antibodies and STAT3 antibodies.
6 receptor turnover rate. IL-6 receptors are known to be internalized by endocytosis once they bind to IL-6. 18 We examined the rate of IL-6 receptor turnover in ANBL6 and CESS cells. PE-conjugated anti-gp130 was used in flow cytometry to examine cell surface gp130. One dose of 10 ng/ml IL-6 was added to cell cultures for 5 min and was washed off. The flow cytometric studies show a similar gp130 turnover rate between ANBL6 and CESS cells (Figure 4a ). gp130 was rapidly lost and reappeared on the cell surface after about 4 to 6 h (Figure 4a ). However, if IL-6 was left in the culture, gp130 was found to be consistently low on the surface of all cells and resurfacing of gp130 was not detected over time (data not shown). This was likely due to the continuous rapid internalization after receptors were re-expressed on the cell surface. Although gp130 recycled on both ANBL6 and CESS cells, another explanation could be due to the inability of recycling of only gp80 in CESS cells, the IL-6 binding subunit. Soluble IL-6 receptor is known to induce and enhance IL-6 signaling by direct stimulation of gp130. 19 We then added 15 ng/ml soluble IL-6 receptor (IL-6sR) to the IL-6-induced CESS cells before IL-6 addition. To ensure the disappearance of STAT3 activation was not due to the lack of IL-6R, additional IL-6sR was added at 15 min before the time of cell harvest (Figure 4b) . Different concentrations as high as 50 ng/ml of IL-6sR were tested and no further activation of DNA binding activity of STAT3. Ten ng/ml of IL-6 was added to cultures. Nuclear extracts were collected at the times indicated. Ten ng of nuclear extracts were used at each time point. 32 P-labeled SIE probe was used to incubate with the nuclear extracts. Mixtures were run on a polyacrylamide gel. NF-kB probe was used to demonstrate equal loading.
Figure 4
Comparison of IL-6 R internalization in CESS and ANBL6 cells and the effect of addition of IL-6 soluble receptor in STAT3 activation in CESS cells. (a) Ten ng/ml of IL-6 was added to cultures for 5 min and then washed out. 1 × 10 6 cells were collected and washed at the times indicated and chilled on ice. PE-linked anti-gp130 antibodies were used to stain the cells at 4°C to determine the amount of gp130 on the cell surface. Cells were washed in ice-cold 1× PBS after antibody incubation and gp130 intensities on cells surface were examined by flow cytometry. (b) Fifty ng/ml IL-6sR was added 5 min prior to the various time points indicated to the IL-6 stimulated lymphoblast CESS cells. Cell lysates were collected and used for Western blot.
STAT3 was detected. Activation of STAT3 in CESS cells remained transient (Figure 4b) . As a result, the difference of STAT3 activation between the myeloma and lymphoblastoid cell lines was not likely to be caused by the difference of receptor turnover rate or the lack of IL-6R on the cell surface.
Leukemia
Figure 5
Expression level of bcl-XL and c-myc in CESS and ANBL6 cells after IL-6 addition. ANBL6 and CESS whole cell lysates (wcl) were collected at the times indicated. Ten ng/ml of IL-6 was added to cultures every 12 h. One hundred g of wcl was loaded in each lane. The indicated primary antibodies were used for Western blotting. Actin was used as loading control.
bcl-X L and c-myc are up-regulated in myeloma cells but not in lymphoblast CESS cells
We and others have shown that IL-6 can up-regulate bcl-2 and bcl-X L . 9, 20, 21 However, we show that IL-6 was not able to induce bcl-XL up-regulation in lymphoblast CESS cells which responded to IL-6 by terminal differentiation, cell cycle arrest, and apoptosis ( Figure 5 ). Others have also reported that IL-6 can change c-myc expression to alter cell growth. [22] [23] [24] Western blot analysis shows c-myc up-regulation in ANBL6 but not in CESS cells ( Figure 5 ). The kinetics of bcl-X L and c-myc expression correlated closely to the prolonged STAT3 activation upon IL-6 stimulation and cell fate in our model system (Figures 2a and 5) .
Leukemia
No phosphorylation of SHP-2 was detected in myeloma cell lines but was detected in lymphoblast CESS cells
Upon IL-6 stimulation, tyrosine residues on the signaling subunit gp130 are rapidly phosphorylated. 25, 26 Src homology 2 (SH2) containing proteins are then recruited and are able to bind to the phosphorylated tyrosine residues on the gp130. Among those, STAT3 and SHP-2 are rapidly recruited to the gp130. SHP-2 is a protein tyrosine phosphatase that has been suggested to be involved in the negative regulation of cytokine receptors that utilize gp130. [25] [26] [27] SHP-2 phosphorylation has also been suggested to activate SHP-2 phosphatase activity. 25 Because of the potential importance of SHP-2 in cytokine signaling, we examined the ability of SHP-2 to dock to the gp130 in myeloma and lymphoblast cells upon IL-6 stimulation, and the subsequent phosphorylation. IL-6 stimulated cells were collected at the times indicated, and cell lysates were subjected to gp130 immunoprecipitation (Figure 6a) . In response to IL-6, gp130 was found to be phosphorylated in a transient manner in all of the cell lines tested (Figure 6a ). SHP-2 was also effectively recruited to gp130, as it co-precipitated with gp130 in ANBL6, Kas6/1, and CESS cells (Figure 6a ). How-
Figure 6
Phosphorylation of gp130, STAT3, and SHP-2 in CESS, ANBL6, KAS6/1, and MM patients cells after addition of IL-6. Whole cell lysates were collected at the times indicated after 10 ng/ml IL-6 addition. (a) Five g of anti-gp130 antibodies were used in immunoprecipitation in 100 g of lysates. Immunoprecipitated products were run out on SDS-PAGE and Western blotting was performed using the antibodies indicated. Myeloma U266 cells gave similar results as ANBL6. (b) Immunoprecipitation was performed with SHP-2 antibodies. ANBL6 whole cell lysates were collected at various time points after 10 ng/ml of IL-6 stimulation as indicated. (c) Fifty g of MM patient samples were examined to detect STAT3 activation and SHP-2 phosphorylation. (d) Five hundred m of the phosphatase inhibitor, sodium orthovanadate (SOV), was used to pretreat CESS cells for 30 min before the addition of 10 ng/ml of IL-6. Cell lysates were collected and used for Western blot. ever, the gp130 associated SHP-2 was not phosphorylated in the myeloma cells tested (Figures 6a) . In contrast, SHP-2 phosphorylation in CESS cells followed the same transient pattern as the gp130 phosphorylation (Figure 6a) .
Next, we decided to look at total SHP-2 and its phosphorylation upon IL-6 stimulation. Immunoprecipitation of SHP-2 was performed (Figure 6b) . Phosphorylation of SHP-2 in ANBL6 cells after IL-6 stimulation was not detected (Figure 6b ). Co-immunoprecipitation of STAT3 with SHP-2 was also seen. This was mediated through the transient docking of SHP-2 and STAT3 to the transient phosphorylated gp130. Two samples from myeloma patients were immunoprecipitated with gp130 to look at STAT3 activation and SHP-2 phosphorylation. Activated STAT3 was found to be associated with the immunocomplex (Figure 6c ). SHP-2 was also recruited to gp130 but again no phosphorylation of SHP-2 was detected (Figure 6c ). To investigate whether phosphatases have any role in the duration of STAT3 activation, phosphatase inhibitor sodium orthovanadate was used to treat lymphoblast CESS cells. The use of the phosphatase inhibitor indeed prolonged the activation of STAT3 of the pretreated lymphoblast CESS cells (Figure 6d ).
Discussion
The role of IL-6 in promoting normal B cell terminal differentiation into an immunoglobulin secretory cell has been studied and demonstrated. [3] [4] [5] Because of the pleiotropic nature of this cytokine, IL-6 is also involved in cell proliferation and survival in other cell types including myeloma plasma cells. [1] [2] [3] Although the exact mechanisms of the IL-6 signaling in each biological response are still unclear, STAT3 seems to play a central and essential role in all the responses. From early studies of the IL-3-dependent pro-B cell line, BAF/B03, Fukada et al 28, 29 showed that STAT3 activation is essential for gp130-induced proliferation and for up-regulation of cyclins and down-regulation of p21 and p27 in BAF/B03 cells. Furthermore, dominant-negative STAT3 was shown to inhibit gp130-mediated anti-apoptosis, indicating that STAT3 is required for at least two distinct signaling pathways, one for cell cycle progression and one for cell survival.
28,29 Nakajima et al 22 showed that STAT3 activation is required for the gp130-mediated macrophage differentiation and growth arrest of M1 cells. The roles for STAT3 in G-CSF-induced granulocyte differentiation and in CNTF-and OSM-induced astrocyte differentiation in vitro have also been reported. [30] [31] [32] Recently, constitutive activated STAT3 in myeloma was suggested to confer resistance to apoptosis.
14 From this study and our previous studies, 9 we show that IL-6 induces a proliferative response in the malignant plasma cells by inducing expression of cyclins, repressing cdk inhibitors, and up-regulating c-myc expression 33 ( Figure 5 ). Furthermore, IL-6 provides anti-apoptotic signals to the malignant plasma cells to overcome death by up-regulating bcl-2 and bcl-X L . 9, 20, 21 In this study, we asked what potential differences or deregulation in IL-6 signaling in myeloma can be identified when compared to lymphoblasts that responsed to IL-6 by cell cycle arrest, terminal differentiation, and apoptosis. We were able to identify distinct IL-6 signaling differences that correlate with the biological responses of the IL-6 and cell fate in myeloma and lymphoblast cell lines.
Our results along with others 34 show that IL-6 induces cell cycle arrest, terminal differentiation, and apoptosis in lymphoblast CESS cells but promotes cell growth in myeloma cells (Figures 1 and 2a) . We identified distinct STAT3 activation kinetics between the cell lines (Figure 2a) . The prolonged and sustained presence of phosphorylated STAT3 in ANBL6, U266, and U266-p53 (Figure 2a and b) suggests a prolonged activation of STAT3 which was later confirmed by DNA binding assays (Figure 3 ). When we withdrew IL-6 from myeloma ANBL6 or U266-p53 cells, the level of phosphorylated STAT3 slowly decreased in 2 to 4 days (data not shown). Constitutive activation of STAT3 in myeloma U266 cells was recently reported.
14 Interestingly, by introducing wild-type p53 into U266, an IL-6-independent myeloma cell line, we were able to block its autocrine IL-6 expression hence making U266 cells IL-6 dependent for growth. 8 These cells then show a prolonged STAT3 activation only upon IL-6 stimulation rather than constitutive activation seen in the autocrine IL-6 parental line (Figure 2b ). This suggests the sustained activation of STAT3 seen in U266 was due to the IL-6 autocrine loop. Thus far, no defects have been described on tyrosine kinases, STAT proteins, or negative regulators in the IL-6 signaling in myeloma that can lead to the constitutive activation of STAT3 without continuous IL-6 stimulation.
Signaling kinetics and duration in cells has been described to alter or give rise to distinct cell fate. 16 The well-known PC12 model cell line proliferates or differentiates depending Leukemia on the duration of the signal transduction. Sustained Ras activation by nerve growth factor (NGF) leads to differentiation but transient Ras activation by epidermal growth factor (EGF) only induces neurite outgrowth from PC12 cells. In this study, we observed distinct signaling kinetics in STAT3 activation by IL-6 in our model cell lines (Figure 2a and b) . Prolonged activation of STAT3 in myeloma ANBL6 cells results in expression of higher levels of bcl-X L and c-myc ( Figure 5 ). They respond to IL-6 by proliferating (Figure 1) . In contrast, bcl-X L and cmyc were not altered by IL-6 in lymphoblast CESS cells which terminally differentiated, cell cycle arrested, and underwent apoptosis in response to a transient activation of STAT3 by IL-6 (Figures 1 and 5) . This is the first comparison of STAT3 activation kinetics in myeloma and lymphoblast cells by IL-6. Our results correlate closely with the alteration of bcl-X L or cmyc expression in myeloma cells by prolonged activation of STAT3. In fact, by blocking STAT3 activation in U266, myeloma cells rapidly undergo apoptosis.
14 Protein tyrosine phosphatase SHP-2 has been suggested to play a role in positive and negative regulation of cytokine signaling. [25] [26] [27] It is known that SHP-2 is phosphorylated rapidly when stimulated with IL-6 through the gp130 subunit. 35 When gp130-associated SHP-2 was examined in our model system, it was not phosphorylated upon IL-6 stimulation in myeloma cells (Figure 6a ). However, phosphorylated gp130-associated SHP-2 was detected in lymphoblast CESS cells (Figure 6a) . A recent report showed that cytoplasmic SHP-2 phosphorylation in myeloma cells can be detected as early as 8 h after IL-6 stimulation. 36 However, it is not clear if early SHP-2 activation or phosphorylation was observed. 36 The difference in SHP-2 response after IL-6 stimulation, in our system and that of others, may be a result of genetic heterogeneity among multiple myeloma cells. Immunoprecipitation of SHP-2 or gp130 from our MM cell lines did not give us any indication of SHP-2 phosphorylation even as late as 8 h after continuous IL-6 stimulation (Figure 6a and b) . Furthermore, results using myeloma patient samples supported the absence of phosphorylation of SHP-2 seen in the MM cell lines upon IL-6 stimulation (Figure 6c ). Phosphatase inhibitor study further suggested the role of phosphatases in the duration of STAT3 activation, because the transient activation of STAT3 in lymphoblast CESS cells was no longer observed after being pretreated with phosphatase inhibitor sodium orthovanadate (Figure 6d ). Activated STAT3 could still be detected at 6 h after IL-6 stimulation compared to CESS cells that were not treated with the inhibitor (Figure 6d ). Although there is no clear evidence that SHP-2 participates directly in STAT3 deactivation, the inability of phosphorylation of SHP-2 that we observed in myeloma, along with other reports, 25, 26 may lead to the distinct IL-6 signaling seen in our model system. We have also examined the SOCS family members SOCS1 and 3 which have been suggested to be involved in IL-6-negative regulation. 37 However, we did not observe any distinct differences in SOCS1 and SOCS3 expression pattern in the cell lines upon IL-6 stimulation (data not shown).
In conclusion, recent reports suggest an important role of STAT3 in fundamental biological responses in normal and malignant cells. 17 Our results suggest a potential correlation between STAT3 signaling kinetics and cell fate. These model systems also allow us to identify IL-6 signaling deregulation which may be associated with malignant plasma cell growth and survival. Further examination of the role of these pathways on therapeutic response will be an important future consideration.
